• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

Introduction to 3-Butoxyazetidine Hydrochloride (CAS No: 1309207-94-0)

3-Butoxyazetidine Hydrochloride (CAS No: 1309207-94-0) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, characterized by its hydrochloride salt form, belongs to the azetidine class of heterocyclic compounds, which are widely recognized for their diverse biological activities and synthetic utility. The structural motif of 3-butoxyazetidine incorporates a butyl ether group attached to a five-membered azetidine ring, providing a unique scaffold that can be exploited for various chemical modifications and biological applications.

The chemical structure of 3-butoxyazetidine hydrochloride can be represented as C?H??NO·HCl, where the hydrochloride salt enhances its solubility in aqueous systems, making it a valuable intermediate in drug formulation and biochemical assays. The presence of the butoxy group introduces steric and electronic effects that can influence the reactivity and binding affinity of the molecule, making it a versatile building block in medicinal chemistry.

In recent years, 3-butoxyazetidine hydrochloride has been explored as a key intermediate in the synthesis of bioactive molecules. Its azetidine core is particularly interesting because it mimics the conformational flexibility of natural amino acid residues, such as proline, while offering additional functional handles for derivatization. This property has made it a candidate for developing novel pharmacophores targeting various therapeutic areas.

One of the most compelling aspects of 3-butoxyazetidine hydrochloride is its potential application in the development of enzyme inhibitors. The azetidine ring can serve as a scaffold to interact with specific enzymatic active sites, particularly those involving proteases and kinases. For instance, studies have shown that derivatives of azetidine have been effective in inhibiting bacterial proteases, which are crucial targets in antibiotic development. The butoxy group further modulates the interaction by providing steric hindrance or by participating in hydrogen bonding networks, enhancing the binding affinity.

Moreover, 3-butoxyazetidine hydrochloride has been investigated in the context of drug delivery systems. Its ability to form stable complexes with other molecules makes it an excellent candidate for encapsulating therapeutic agents. This property is particularly relevant in targeted drug delivery, where 3-butoxyazetidine hydrochloride-based carriers can improve bioavailability and reduce off-target effects. Recent advancements in nanotechnology have enabled the design of nanoparticles functionalized with 3-butoxyazetidine hydrochloride moieties, which show promise in delivering payloads to specific cellular compartments.

The pharmaceutical industry has also explored 3-butoxyazetidine hydrochloride as a precursor for synthesizing novel therapeutics. Its structural features allow for easy functionalization at multiple positions, enabling the creation of diverse chemical libraries for high-throughput screening. For example, researchers have utilized 3-butoxyazetidine hydrochloride to develop small-molecule inhibitors targeting inflammatory pathways. These inhibitors have shown promise in preclinical studies for treating conditions such as rheumatoid arthritis and inflammatory bowel disease.

Another area where 3-butoxyazetidine hydrochloride has found utility is in materials science. The compound’s ability to form coordination complexes with metal ions has led to its use in catalysis and as a ligand in metal-organic frameworks (MOFs). These MOFs have applications ranging from gas storage and separation to catalytic transformations, underscoring the versatility of 3-butoxyazetidine hydrochloride beyond pharmaceuticals.

In conclusion, 3-Butoxyazetidine Hydrochloride (CAS No: 1309207-94-0) represents a fascinating compound with broad applications across multiple scientific disciplines. Its unique structural features make it an invaluable tool for synthetic chemists and biologists alike. As research continues to uncover new methodologies and applications, the potential uses of 3-butoxyazetidine hydrochloride are expected to expand further, solidifying its role as a cornerstone molecule in modern chemical biology.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)